It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2016
  5. Anti-epileptic Drug E Keppra® (generic name: levetiracetam) Obtains Additional Indication of Adjunctive Therapy for Generalized Tonic-Clonic Seizures in Japan

February 29, 2016

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

Anti-epileptic Drug E Keppra® (generic name: levetiracetam) Obtains Additional Indication of Adjunctive Therapy for Generalized Tonic-Clonic Seizures in Japan

Otsuka Pharmaceutical Co., Ltd. and UCB Japan Co., Ltd. today announced that E Keppra® was approved in Japan for an additional indication as adjunctive therapy with other anti-epileptic drugs for generalized tonic-clonic seizures in adult patients and pediatric patients aged four years and over with epilepsy showing inadequate responses to other anti-epileptic drugs. Otsuka Pharmaceutical and UCB Japan are engaged in the co-development and co-commercialization of E Keppra® in Japan. The formulations approved for this indication include E Keppra® Tablets 250 mg and 500 mg, E Keppra® Dry Syrup 50%, and E Keppra® for IV Infusion 500 mg.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases